Elsevier

Journal of Hepatology

Volume 62, Issue 5, May 2015, Pages 1187-1195
Journal of Hepatology

Review
Transarterial chemoembolization: Modalities, indication, and patient selection

https://doi.org/10.1016/j.jhep.2015.02.010Get rights and content
Under a Creative Commons license
open access

Summary

Transarterial chemoembolization (TACE) is the standard of care for patients with intermediate stage hepatocellular carcinoma (BCLC B). Further improvement of the use of TACE was the subject of intense clinical research over the past years. The introduction of DEB-TACE brought more technical standardization and reduction of TACE related toxicity. The use of dynamic radiologic response evaluation criteria (EASL, mRECIST), uncovered the prognostic significance of objective tumor response. Finally, new approaches for better patient selection for initial and subsequent TACE treatment schedules will limit the use of TACE to some extent but have the potential to improve outcome for patients at risk for TACE-induced harm.

Keywords

TACE
HCC
Patient selection
Response
mRECIST
Overall survival
Hepatocellular carcinoma
Intermediate stage

Cited by (0)